About this episode

The episode discusses a novel drug candidate targeting multiple sclerosis and its potential impact on treatment.

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). What makes MS particularly devastating is its progressive nature. Rather than…

More episodes of The BioMedWire Podcast

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis · June 26, 2026 · 21 min
• Next-Generation DNA Repair Therapies Open New Frontiers in Oncology · June 26, 2026 · 21 min
• Next-Generation DNA Repair Therapies Open New Frontiers in Oncology [Video Edition] · June 26, 2026 · 21 min

Explore listener stats, chart rankings, contacts and more on the The BioMedWire Podcast podcast page.